- Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA
- Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate
- Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom
- Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
- Anti-Influenza Drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 Patients
- Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
- MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
- Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer
- Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine
- Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
- Lilly Announces Proof of Concept Data for Neutralizing Antibody LY-CoV555 in the COVID-19 Outpatient Setting
- Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
- Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
- Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients
- Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program